BRPI0519040A2 - tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos - Google Patents

tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos

Info

Publication number
BRPI0519040A2
BRPI0519040A2 BRPI0519040-1A BRPI0519040A BRPI0519040A2 BR PI0519040 A2 BRPI0519040 A2 BR PI0519040A2 BR PI0519040 A BRPI0519040 A BR PI0519040A BR PI0519040 A2 BRPI0519040 A2 BR PI0519040A2
Authority
BR
Brazil
Prior art keywords
thiazolidinones
production
methasubstituted
medicinal
plk
Prior art date
Application number
BRPI0519040-1A
Other languages
English (en)
Inventor
Volker Klaus Schulze
Knut Eis
Lars Wortmann
Dirk Kosemund
Olaf Prien
Gerhard Siemeister
Holger Hess-Stumpp
Uwe Eberspaecher
Dominic E A Brittain
Imadul Islam
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35895206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0519040(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004061503A external-priority patent/DE102004061503A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0519040A2 publication Critical patent/BRPI0519040A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

TIAZOLIDINONAS METASSUBSTITUÍDAS, SUA PRODUÇçO E USO COMO MEDICAMENTOS. A invenção refere-se a tiazolidinonas da fórmula geral (I), bem como sua produção e uso como inibidores da quinase do tipo Polo (Plk) para o tratamento de diversas doenças.
BRPI0519040-1A 2004-12-15 2005-12-12 tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos BRPI0519040A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004061503A DE102004061503A1 (de) 2004-12-15 2004-12-15 Metasubstituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US63777704P 2004-12-22 2004-12-22
PCT/EP2005/013418 WO2006063806A1 (de) 2004-12-15 2005-12-12 Metasubstituierte thiazolidinone, deren herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
BRPI0519040A2 true BRPI0519040A2 (pt) 2009-01-13

Family

ID=35895206

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519040-1A BRPI0519040A2 (pt) 2004-12-15 2005-12-12 tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos

Country Status (18)

Country Link
US (2) US20070015759A1 (pt)
EP (1) EP1824834A1 (pt)
JP (1) JP2008524139A (pt)
KR (1) KR20070092740A (pt)
AR (1) AR055698A1 (pt)
AU (1) AU2005315835A1 (pt)
BR (1) BRPI0519040A2 (pt)
CA (1) CA2590396A1 (pt)
CR (1) CR9183A (pt)
GT (1) GT200500366A (pt)
IL (1) IL183395A0 (pt)
MX (1) MX2007007245A (pt)
NO (1) NO20073631L (pt)
PA (1) PA8656501A1 (pt)
PE (1) PE20061157A1 (pt)
TW (1) TW200628458A (pt)
UY (1) UY29264A1 (pt)
WO (1) WO2006063806A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
EP1989330A4 (en) * 2006-01-31 2009-10-21 Elan Pharm Inc ALPHA-SYNUCLEINE KINASE
EP2247748A2 (en) * 2008-02-13 2010-11-10 Elan Pharma International Limited Alpha-synuclein kinase
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 (アリール)ジフルオロ酢酸エステル誘導体及びその製造方法
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
CN105228982B (zh) * 2013-03-20 2018-03-27 拜耳制药股份公司 用于治疗过度增殖性病症的3‑乙酰基氨基‑1‑(苯基‑杂芳基‑氨基羰基或苯基‑杂芳基‑羰基氨基)苯衍生物
US20160052898A1 (en) * 2013-03-20 2016-02-25 Bayer Pharma Aktiengesellschaft Novel compounds
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
TN2016000550A1 (en) * 2014-06-16 2018-04-04 Centre Hospitalier Regional Univ De Lille Chru Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EP4479042A1 (en) 2022-02-18 2024-12-25 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501794A1 (de) * 2002-05-03 2005-02-02 Schering Aktiengesellschaft Thiazolidinone und ihre verwendung als polo like kinase inhibitoren
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PA8656501A1 (es) 2006-09-08
JP2008524139A (ja) 2008-07-10
IL183395A0 (en) 2007-09-20
PE20061157A1 (es) 2006-11-16
WO2006063806A1 (de) 2006-06-22
US20100048891A1 (en) 2010-02-25
CR9183A (es) 2008-01-21
KR20070092740A (ko) 2007-09-13
NO20073631L (no) 2007-09-12
UY29264A1 (es) 2006-06-30
AR055698A1 (es) 2007-09-05
MX2007007245A (es) 2008-02-25
CA2590396A1 (en) 2006-06-22
US20070015759A1 (en) 2007-01-18
EP1824834A1 (de) 2007-08-29
GT200500366A (es) 2006-12-04
AU2005315835A1 (en) 2006-06-22
TW200628458A (en) 2006-08-16

Similar Documents

Publication Publication Date Title
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
CR9183A (es) Tiazolidinonas metasustituidas, su preparacion y su uso como medicamento
ECSP10010216A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
UY31484A1 (es) Piperidinas heteroaril-sustituidas
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
DK2150530T3 (da) Substituerede sulfonamid-derivater
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
BRPI0514833A (pt) fenilaminotiazóis substituìdos e seu uso
BRPI0514731A (pt) derivados de pirimidina
ATE506340T1 (de) 12-aryl-prostaglandin-analoga
CL2008000596A1 (es) Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
ECSP066588A (es) Tiazolidinonas, su preparación y su uso como medicamentos
BRPI0606140A2 (pt) tiazolidinonas, preparação e uso das mesmas como medicamento
UY30550A1 (es) Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
UY30207A1 (es) Nuevos beta-agonistas enantionéricamente puros, procedimientos para su preparacion y su uso como medicamentos
MX2007013306A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.
CR9323A (es) TIAZOLIDINONAS COMO INHIBIDORAS DE LAS POLOQUINASAS (Plk) COMO MEDICAMENTO
DE502007006951D1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]